Literature DB >> 32323311

ADAMTS19-associated heart valve defects: Novel genetic variants consolidating a recognizable cardiac phenotype.

Salam Massadeh1,2, Amal Alhashem3,4, Ingrid M B H van de Laar5, Fahad Alhabshan6, Natalia Ordonez7, Salem Alawbathani7, Suliman Khan7, Mohamed S Kabbani6, Farah Chaikhouni6, Atia Sheereen1, Iman Almohammed1,2, Bader Alghamdi1, Ingrid Frohn-Mulder8, Salim Ahmad9, Christian Beetz7, Peter Bauer7, Marja W Wessels5, Manal Alaamery1,2, Aida M Bertoli-Avella7.   

Abstract

Recently, ADAMTS19 was identified as a novel causative gene for autosomal recessive heart valve disease (HVD), affecting mainly the aortic and pulmonary valves. Exome sequencing and data repository (CentoMD) analyses were performed to identify patients with ADAMTS19 variants (two families). A third family was recognized based on cardiac phenotypic similarities and SNP array homozygosity. Three novel loss of function (LoF) variants were identified in six patients from three families. Clinically, all patients presented anomalies of the aortic/pulmonary valves, which included thickening of valve leaflets, stenosis and insufficiency. Three patients had (recurrent) subaortic membrane, suggesting that ADAMTS19 is the first gene identified related to discrete subaortic stenosis. One case presented a bi-commissural pulmonary valve. All patients displayed some degree of atrioventricular valve insufficiency. Other cardiac anomalies included atrial/ventricular septal defects, persistent ductus arteriosus, and mild dilated ascending aorta. Our findings confirm that biallelic LoF variants in ADAMTS19 are causative of a specific and recognizable cardiac phenotype. We recommend considering ADAMTS19 genetic testing in all patients with multiple semilunar valve abnormalities, particularly in the presence of subaortic membrane. ADAMTS19 screening in patients with semilunar valve abnormalities is needed to estimate the frequency of the HVD related phenotype, which might be not so rare.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990ADAMTS19; aortic valve stenosis; pulmonary stenosis; subaortic membrane

Mesh:

Substances:

Year:  2020        PMID: 32323311     DOI: 10.1111/cge.13760

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  4 in total

1.  Novel Autosomal Recessive Splice-Altering Variant in PRKD1 Is Associated with Congenital Heart Disease.

Authors:  Salam Massadeh; Maha Albeladi; Nour Albesher; Fahad Alhabshan; Kapil Dev Kampe; Farah Chaikhouni; Mohamed S Kabbani; Christian Beetz; Manal Alaamery
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

Review 2.  The importance of genetic testing for dystonia patients and translational research.

Authors:  Jelena Pozojevic; Christian Beetz; Ana Westenberger
Journal:  J Neural Transm (Vienna)       Date:  2021-04-19       Impact factor: 3.575

Review 3.  Consanguinity and Congenital Heart Disease Susceptibility: Insights into Rare Genetic Variations in Saudi Arabia.

Authors:  Nour Albesher; Salam Massadeh; Sabah M Hassan; Manal Alaamery
Journal:  Genes (Basel)       Date:  2022-02-16       Impact factor: 4.096

4.  Combining exome/genome sequencing with data repository analysis reveals novel gene-disease associations for a wide range of genetic disorders.

Authors:  Aida M Bertoli-Avella; Krishna K Kandaswamy; Suliman Khan; Natalia Ordonez-Herrera; Kornelia Tripolszki; Christian Beetz; Maria Eugenia Rocha; Alize Urzi; Ronja Hotakainen; Anika Leubauer; Ruslan Al-Ali; Vasiliki Karageorgou; Oana Moldovan; Patrícia Dias; Amal Alhashem; Brahim Tabarki; Mohammed A Albalwi; Abdulrahman Faiz Alswaid; Zuhair N Al-Hassnan; Malak Ali Alghamdi; Zahra Hadipour; Fatemeh Hadipour; Nadia Al Hashmi; Lihadh Al-Gazali; Huma Cheema; Maha S Zaki; Irina Hüning; Ahmed Alfares; Wafaa Eyaid; Fuad Al Mutairi; Majid Alfadhel; Fowzan S Alkuraya; Nouriya Abbas Al-Sannaa; Aisha M AlShamsi; Najim Ameziane; Arndt Rolfs; Peter Bauer
Journal:  Genet Med       Date:  2021-04-19       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.